Liliana Guelfand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liliana Guelfand has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Inés Toranzo
Departamento Micología, INEI-ANLIS “Dr. Carlos G. Malbrán” Laboratorio Nacional de Referencia en Micología Clínica, Buenos Aires, Argentina
1 shared publication - Agustina Forastiero
Microbiología, Servicio Laboratorio, Hospital Británico de Buenos Aires , Buenos Aires
1 shared publication Ana Ruth Laborde
Fundación para Combatir la Leucemia (FUNDALEU), Buenos Aires, Argentina
1 shared publication- Claudia E. Frola
Division of Infectious Diseases, Hospital Juan A. Fernández , Buenos Aires
1 shared publication - Cristina Elena Canteros
Departamento Micología, INEI-ANLIS “Dr. Carlos G. Malbrán” Laboratorio Nacional de Referencia en Micología Clínica, Buenos Aires, Argentina
1 shared publication Facundo Muise-Acevedo
Departamento Micología, INEI-ANLIS “Dr. Carlos G. Malbrán” Laboratorio Nacional de Referencia en Micología Clínica, Buenos Aires, Argentina
1 shared publication
Latest Publications
- 4 November 2025
- Published by Springer Nature in Mycopathologia
- Vol. 190 (6) , 1-10
Standardization and Clinical Evaluation of a Real-Time PCR Assay for the Diagnosis of Pneumocystis jirovecii Pneumonia
Background Pneumocystis jirovecii pneumonia (PjP) is a life-threatening infection in immunocompromised individuals. Its diagnosis remains challenging, especially in microscopy-negative cases. This study aimed to standardize and validate a qPCR assay targeting the mtLSU rRNA gene for detecting P. jirovecii DNA in respiratory samples from patients in Argentina. Materials and Methods The assay was optimized using plasmid dilutions containing the target gene. Analytical specificity was evaluated against 60 fungal, 21 mycobacterial, and 16 bacterial species. Clinical validation included 101 respiratory samples from symptomatic patients and 37 from healthy individuals. An internal positive control (IPC) was included in all reactions to detect inhibitors. Results The qPCR assay showed a detection limit of 8.8 copies/μL and no cross-reactivity. Among microscopy-confirmed cases, 95.5% were qPCR-positive. Notably, 14.9% of microscopy-negative but clinically compatible cases tested positive. ROC analysis yielded an AUC of 0.96, with an optimal Ct cutoff ≤ 36, providing 90.7% sensitivity and 95.8% specificity. No healthy controls tested positive. A “grey zone” (Ct 36–37.8) was observed, requiring clinical correlation. Conclusions This qPCR assay is highly sensitive and specific, offering a valuable diagnostic tool for PjP. Its performance supports implementation in routine diagnostics, especially when microscopy is inconclusive. However, interpretation in the grey zone requires complementary clinical or biomarker data.
- 4 November 2025
- Published by Springer Nature in Mycopathologia
- Vol. 190 (6) , 1-10
Standardization and Clinical Evaluation of a Real-Time PCR Assay for the Diagnosis of Pneumocystis jirovecii Pneumonia
Background Pneumocystis jirovecii pneumonia (PjP) is a life-threatening infection in immunocompromised individuals. Its diagnosis remains challenging, especially in microscopy-negative cases. This study aimed to standardize and validate a qPCR assay targeting the mtLSU rRNA gene for detecting P. jirovecii DNA in respiratory samples from patients in Argentina. Materials and Methods The assay was optimized using plasmid dilutions containing the target gene. Analytical specificity was evaluated against 60 fungal, 21 mycobacterial, and 16 bacterial species. Clinical validation included 101 respiratory samples from symptomatic patients and 37 from healthy individuals. An internal positive control (IPC) was included in all reactions to detect inhibitors. Results The qPCR assay showed a detection limit of 8.8 copies/μL and no cross-reactivity. Among microscopy-confirmed cases, 95.5% were qPCR-positive. Notably, 14.9% of microscopy-negative but clinically compatible cases tested positive. ROC analysis yielded an AUC of 0.96, with an optimal Ct cutoff ≤ 36, providing 90.7% sensitivity and 95.8% specificity. No healthy controls tested positive. A “grey zone” (Ct 36–37.8) was observed, requiring clinical correlation. Conclusions This qPCR assay is highly sensitive and specific, offering a valuable diagnostic tool for PjP. Its performance supports implementation in routine diagnostics, especially when microscopy is inconclusive. However, interpretation in the grey zone requires complementary clinical or biomarker data.